{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:43:21Z","timestamp":1793598201207,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Cirius Therapeutics, Inc"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jhep.2019.10.023","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T19:54:00Z","timestamp":1572897240000},"page":"613-626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":211,"title":["Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study"],"prefix":"10.1016","volume":"72","author":[{"given":"Stephen A.","family":"Harrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naim","family":"Alkhouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth A.","family":"Davison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3933-8626","authenticated-orcid":false,"given":"Jerry R.","family":"Colca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Cusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9306-1288","authenticated-orcid":false,"given":"Orville","family":"Kolterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad","family":"Cotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6049-8328","authenticated-orcid":false,"given":"Howard C.","family":"Dittrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2019.10.023_b0005","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","article-title":"The global NAFLD epidemic","volume":"10","author":"Loomba","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.10.023_b0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.28524","article-title":"The globalization of nonalcoholic fatty liver disease: prevalence and impact on world health","volume":"64","author":"Rinella","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.10.023_b0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","article-title":"NAFLD and diabetes mellitus","volume":"14","author":"Tilg","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.10.023_b0020","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2337\/dc15-1876","article-title":"Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes","volume":"39","author":"Lomonaco","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2019.10.023_b0025","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.10.023_b0030","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cmet.2014.08.005","article-title":"Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes","volume":"20","author":"Soccio","year":"2014","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2019.10.023_b0035","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2019.10.023_b0040","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.10.023_b0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061551","article-title":"Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)\u2013relationship to newly identified mitochondrial pyruvate carrier proteins","volume":"8","author":"Colca","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jhep.2019.10.023_b0050","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1073\/pnas.1303360110","article-title":"Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier","volume":"110","author":"Divakaruni","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2019.10.023_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/13543784.2013.839659","article-title":"Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases","volume":"23","author":"Colca","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jhep.2019.10.023_b0060","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1517\/17460441.2015.1100164","article-title":"The TZD insulin sensitizer clue provides a new route into diabetes drug discovery","volume":"10","author":"Colca","year":"2015","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.jhep.2019.10.023_b0065","doi-asserted-by":"crossref","first-page":"23537","DOI":"10.1074\/jbc.M112.363960","article-title":"Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor gamma-sparing thiazolidinedione","volume":"287","author":"Chen","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2019.10.023_b0070","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/hep.29025","article-title":"Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis","volume":"65","author":"McCommis","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.10.023_b0075","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hep4.1036","article-title":"Treating fatty liver disease by modulating mitochondrial pyruvate metabolism","volume":"1","author":"Colca","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2019.10.023_b0080","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/13543784.2018.1494153","article-title":"MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis","volume":"27","author":"Colca","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jhep.2019.10.023_b0085","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.10.023_b0090","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1191\/0962280205sm397oa","article-title":"Randomization-based nonparametric methods for the analysis of multicentre trials","volume":"14","author":"LaVange","year":"2005","journal-title":"Stat Methods Med Res"},{"issue":"50","key":"10.1016\/j.jhep.2019.10.023_b0095","first-page":"17","article-title":"NParCov3: a SAS\/IML macro for nonparametric randomization-based analysis of covariance","volume":"2012","author":"Zink","year":"2012","journal-title":"J Stat Softw"},{"key":"10.1016\/j.jhep.2019.10.023_b0100","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/hep.22241","article-title":"A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients","volume":"47","author":"Campos","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.10.023_b0105","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/CIRCHEARTFAILURE.112.969154","article-title":"Evaluating treatment efficacy by multiple end points in phase II acute heart failure clinical trials: analyzing data using a global method","volume":"5","author":"Sun","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jhep.2019.10.023_b0110","unstructured":"(CDER). Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment Guidance for Industry. 2018: 7\u20138."},{"key":"10.1016\/j.jhep.2019.10.023_b0115","unstructured":"European Medicines Agency. Reflection paper on regulatory requirements for the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH). 2018: 7."},{"key":"10.1016\/j.jhep.2019.10.023_b0120","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jhep.2019.10.023_b0125","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.2337\/dc12-1513","article-title":"All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large U.K. primary care database","volume":"36","author":"Taylor","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2019.10.023_b0130","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010214","article-title":"Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)","volume":"97","author":"Golabi","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jhep.2019.10.023_b0135","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13098-017-0237-x","article-title":"Basal hyperinsulinemia beyond a threshold predicts major adverse cardiac events at 1 year after coronary angiogram in type 2 diabetes mellitus: a retrospective cohort study","volume":"9","author":"Srinivasan","year":"2017","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.jhep.2019.10.023_b0140","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/1479164119827604","article-title":"Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial","volume":"16","author":"Kumar","year":"2019","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.jhep.2019.10.023_b0145","doi-asserted-by":"crossref","first-page":"E1709","DOI":"10.1152\/ajpendo.00444.2007","article-title":"Effect of liver fat on insulin clearance","volume":"293","author":"Kotronen","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jhep.2019.10.023_b0150","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijcard.2011.09.039","article-title":"Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population","volume":"162","author":"Doehner","year":"2012","journal-title":"Int J Cardiol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819306506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819306506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:38:04Z","timestamp":1759174684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827819306506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0168827819306506"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2019.10.023","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2019.10.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}